{
    "organizations": [],
    "uuid": "cfe8072493a3bc6582b5e821ccf3ad37916ae14e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-concert-pharmaceuticals-reports-qt/brief-concert-pharmaceuticals-reports-qtrly-loss-per-share-0-26-idUSASB0C88U",
    "ord_in_thread": 0,
    "title": "BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1, 2018 / 12:12 PM / Updated 7 minutes ago BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26 Reuters Staff March 1 (Reuters) - Concert Pharmaceuticals Inc: * CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS * CONCERT PHARMACEUTICALS INC - CTP-543 ON TRACK TO REPORT TOPLINE PHASE 2A RESULTS IN ALOPECIA AREATA BY YEAR-END * CONCERT PHARMACEUTICALS INC - NEW NEUROPSYCHIATRIC PRODUCT CANDIDATE POISED TO ENTER CLINICAL DEVELOPMENT IN 2018 * CONCERT PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.26 * CONCERT PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG COHORTS OF CTP-543 PHASE 2A TRIAL IN Q4 OF 2018 * CONCERT PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, TOTALED $203.2 MILLION VERSUS $96.2 MILLION AS OF DECEMBER 31, 2016 * CONCERT PHARMACEUTICALS INC - EXPECTS ITS CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DECEMBER 31, 2017 TO BE SUFFICIENT TO FUND COMPANY INTO 2021 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-03-01T14:11:00.000+02:00",
    "crawled": "2018-03-01T14:25:35.068+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "report",
        "qtrly",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "march",
        "reuters",
        "concert",
        "pharmaceutical",
        "inc",
        "concert",
        "pharmaceutical",
        "report",
        "year",
        "ended",
        "financial",
        "result",
        "concert",
        "pharmaceutical",
        "inc",
        "track",
        "report",
        "topline",
        "phase",
        "2a",
        "result",
        "alopecia",
        "areata",
        "concert",
        "pharmaceutical",
        "inc",
        "new",
        "neuropsychiatric",
        "product",
        "candidate",
        "poised",
        "enter",
        "clinical",
        "development",
        "concert",
        "pharmaceutical",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "concert",
        "pharmaceutical",
        "inc",
        "expects",
        "report",
        "topline",
        "data",
        "mg",
        "mg",
        "cohort",
        "phase",
        "2a",
        "trial",
        "q4",
        "concert",
        "pharmaceutical",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "dec",
        "totaled",
        "million",
        "versus",
        "million",
        "december",
        "concert",
        "pharmaceutical",
        "inc",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "december",
        "sufficient",
        "fund",
        "company",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}